Cancer Letters
Volume 194, Issue 2 , Pages 155-162 , 15 May 2003

Alternative lengthening of telomeres, telomerase, and cancer

Received 6 September 2002 ,Revised 30 October 2002 ,Accepted 30 October 2002.

References 

  1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl Acad. Sci. USA. 1988;85:6622–6626
  2. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458–460
  3. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 1973;41:181–190
  4. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000;21:477–484
  5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 1997;33:787–791
  6. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997;3:1271–1274
  7. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921–1929
  8. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240–4248
  9. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405–413
  10. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol. 1999;11:318–324
  11. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402:551–555
  12. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat. Genet. 2000;26:447–450
  13. Varley H, Pickett HA, Foxon JL, Reddel RR, Royle NJ. Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. Nat. Genet. 2002;30:301–305
  14. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. Telomerase activity in human renal cell carcinoma. Oncogene. 1996;13:161–166
  15. Scheel C, Schaefer K-L, Jauch A, Keller M, Wai D, Brinkschmidt C, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene. 2001;20:3835–3844
  16. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598–610
  17. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol. Cell. Biol. 2001;21:3862–3875
  18. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum. Mol. Genet. 2001;10:1945–1952
  19. Grobelny JV, Kulp-McEliece M, Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum. Mol. Genet. 2001;10:1953–1961
  20. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad. Sci. USA. 2002;99:12606–12611
  21. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514
  22. Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53–56
  23. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998;92:401–413
  24. Weng N-P, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc. Natl Acad. Sci. USA. 1997;94:10827–10832
  25. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene. 2002;21:564–579
  26. Herrera E, Martı́nez C, Blasco MA. Impaired germinal center reaction in mice with short telomeres. EMBO J. 2000;19:472–481
  27. Roth CW, Kobeski F, Walter MF, Biessmann H. Chromosome end elongation by recombination in the mosquito Anopheles gambiae. Mol. Cell. Biol. 1997;17:5176–5183
  28. Biessmann H, Valgeirsdottir K, Lofsky A, Chin C, Ginther B, Levis RW, et al. HeT-A, a transposable element specifically involved in ‘healing’ broken chromosome ends in Drosophila melanogaster. Mol. Cell. Biol. 1992;12:3910–3918
  29. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295:2446–2449
  30. Wellinger RJ, Ethier K, Labrecque P, Zakian VA. Evidence for a new step in telomere maintenance. Cell. 1996;85:423–433
  31. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 1997;88:657–666
  32. Li B, Lustig AJ. A novel mechanism for telomere size control in Saccharomyces cerevisiae. Genes Dev. 1996;10:1310–1326
  33. Von Zglinicki T, Serra V, Lorenz M, Saretzki G, Lenzen-Grossimlighaus R, Gessner R, et al. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?. Lab. Invest. 2000;80:1739–1747
  34. Von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002;27:339–344
  35. Smogorzewska A, Karlseder J, Holtgreve-Grez H, Jauch A, de Lange T. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr. Biol. 2002;12:1635–1644
  36. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. Proc. Natl Acad. Sci. USA. 1995;92:258–262
  37. Nehlin JO, Skovgaard GL, Bohr VA. The Werner syndrome. A model for the study of human aging. Ann. NY Acad. Sci. 2000;908:167–179
  38. Blasco MA. Opinion: telomerase beyond telomeres. Nat. Rev. Cancer. 2002;2:627–633
  39. Broccoli D, Godley IA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol. Cell. Biol. 1996;16:3765–3772
  40. González-Suárez E, Samper E, Ramı́rez A, Flores JM, Martı́n-Caballero J, Jorcano JL, et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001;20:2619–2630
  41. Gollahon LS, Kraus E, Wu T-A, Yim SO, Strong LC, Shay JW, et al. Telomerase activity during spontaneous immortalization of Li–Fraumeni syndrome skin fibroblasts. Oncogene. 1998;17:709–717
  42. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175–4179
  43. Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, et al. Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents but not against DNA synthesis inhibitors. Cancer Lett. 2002;178:187–197
  44. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999;5:1164–1170
  45. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13:2388–2399
  46. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTα splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2000;2:426–432
  47. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 2001;61:3053–3061
  48. Saretzki G, Ludwig A, Von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 2001;8:827–834
  49. Nakabayashi K, Ogata T, Fujii M, Tahara H, Ide T, Wadhwa R, et al. Decrease in amplified telomeric sequences and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1. Exp. Cell Res. 1997;235:345–353
  50. Perrem K, Bryan TM, Englezou A, Hackl T, Moy EL, Reddel RR. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene. 1999;18:3383–3390
  51. Herbert B-S, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl Acad. Sci. USA. 1999;96:14276–14281
  52. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001;20:6958–6968

PII: S0304-3835(02)00702-4

doi: 10.1016/S0304-3835(02)00702-4

Cancer Letters
Volume 194, Issue 2 , Pages 155-162 , 15 May 2003

Article Tools

* Image Usage & Resolution